Using mRNA expression profiling to determine anticancer drug efficacy.
Pharmacogenomics is a fast-growing field of investigations that aims to further elucidate the inherited nature of interindividual differences in drug disposition and effects, with the ultimate goal of providing a stronger scientific basis for selecting the optimal drug therapy. Providing the right drug for the right patient is an important problem in the treatment of cancer. This is mainly due to the lack of information about the sensitivity of the tumor for a specific treatment modality, such as either chemotherapy or radiation treatment. This presentation highlights two approaches to identify responsiveness to treatment. Both approaches are based on the identification of expression profiles. The first approach concentrates on drug resistance and the second on the signaling pathways leading up to the death of the cell. Both approaches provide expression profiles; however, the more dynamic expression profiling as used to determine the signaling in damage cells promises to be a better determinant for the pharmacogenomic changes in expression profiles and, consequently, a potential better determinant for drug efficacy.
Los
Gerrit
G
UCSD Cancer Center, University of California at San Diego, La Jolla, California 92037-0058, USA. glos@ucsd.edu
Yang
Fei
F
Samimi
Goli
G
Manorek
Gerald
G
Guerorguieva
Ivelina M
IM
Howell
Stephan
S
van Erp
Nielka
N
Breaux
James K
JK
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D012333:RNA, Messenger
D000970:Antineoplastic Agents; D012333:RNA, Messenger; D002945:Cisplatin